Natural Treatments for Lowering DHT and Managing BPH
The evidence-based medical guidelines do not support natural medicines as primary therapy for BPH; instead, FDA-approved 5α-reductase inhibitors (finasteride or dutasteride) are the only proven DHT-lowering treatments that improve clinical outcomes including symptom scores, prostate volume reduction, and prevention of acute urinary retention and surgery. 1
Why Prescription 5-ARIs Are the Standard
The 2021 AUA guidelines establish that finasteride reduces serum DHT by approximately 70% and prostatic tissue DHT by 80%, while dutasteride reduces serum DHT by 95% and prostatic tissue DHT by 94% 1. These medications work by inhibiting the 5α-reductase enzyme that converts testosterone to DHT, leading to:
- 15-25% prostate volume reduction at 6 months 1
- 3-4 point improvement in International Prostate Symptom Score (IPSS) maintained for 6-10 years 1
- Reduced risk of acute urinary retention and need for surgery 1
- Clinical progression prevention (21% vs 36% with placebo in the REDUCE trial) 1
When to Use 5-ARIs
These medications are appropriate when:
- Prostate volume >30cc OR PSA >1.5 ng/mL 1
- Larger glands show more pronounced effects
- Patients can tolerate the 6-month onset time (slower than alpha-blockers) 1
Natural Products: What the Research Shows
While recent preclinical studies (2021-2026) demonstrate that certain natural compounds can reduce DHT and improve BPH markers in animal models, none have the clinical trial evidence showing improved morbidity, mortality, or quality of life outcomes in humans that would justify recommending them over proven therapies.
Compounds With DHT-Lowering Mechanisms (Preclinical Only)
Recent research identifies several natural products that inhibit 5α-reductase in laboratory settings:
Saw palmetto (Serenoa repens), Pygeum africanum, Urtica dioica (nettle root), and Epilobium angustifolium in combination showed 5α-reductase inhibition and reduced inflammatory cytokines (IL-6, TNF-α) in vitro 2
Stigmasterol (plant sterol) reduced serum DHT, prostatic 5α-reductase expression, and androgen receptor expression in testosterone-treated rats 3
Arachis hypogaea root extract (peanut root) reduced DHT by 84% in testosterone-induced BPH mice, with downregulation of inflammatory genes 4
Dihydroartemisinin reduced serum DHT and prostatic 5α-reductase-2 expression in rat BPH models 5
Critical Limitations of Natural Product Evidence
The fundamental problem: all positive natural product studies are either in vitro (test tube) or in vivo animal models 2, 4, 3, 5. The 2021 comprehensive review on natural products for BPH explicitly states that "many mechanistic claims rely on downstream biomarkers and are model-dependent, while direct target-engagement evidence remains limited" 6.
Key gaps include:
- No human clinical trials demonstrating symptom improvement, reduced acute urinary retention, or decreased need for surgery
- Pharmacokinetic data lacking - unclear if compounds reach prostatic tissue in therapeutic concentrations in humans 6
- Standardization problems - variable potency between products 6
- No comparison to proven therapies in head-to-head trials
The Clinical Reality
The 2023 European Association of Urology and 2021 AUA guidelines 7, 1 make no recommendations for natural products as primary therapy because:
- Proven pharmaceutical options exist with decades of safety and efficacy data
- BPH is a progressive disease - the PLESS study showed 5-ARI therapy alters natural history and prevents complications 1
- Watchful waiting is appropriate for mild symptoms (IPSS 1-7), but when treatment is needed, evidence-based therapy should be used 7
Treatment Algorithm Based on Guidelines
For patients with prostate >30cc or PSA >1.5:
- Start alpha-blocker (tamsulosin, doxazosin, terazosin) for rapid symptom relief 7, 1
- Add 5-ARI (finasteride or dutasteride) for DHT reduction and disease modification 1
- Combination therapy superior to monotherapy for preventing progression 7
For patients with erectile dysfunction and BPH:
- Consider PDE5 inhibitor (tadalafil) as initial therapy 1
Important Caveats
If a patient insists on trying natural products:
- They should understand these are not substitutes for proven therapy when treatment is indicated
- Monitor for disease progression with symptom scores, flow rates, and post-void residuals
- Do not delay effective treatment if symptoms worsen or complications develop
- Saw palmetto and nettle root have the longest traditional use, but lack rigorous clinical validation 8, 6
PSA monitoring consideration: Unlike prescription 5-ARIs which reduce PSA by ~50% (requiring doubling of measured values for cancer screening) 1, natural products' effects on PSA are unknown, potentially complicating prostate cancer surveillance.
The evidence hierarchy is clear: prescription 5α-reductase inhibitors are the only DHT-lowering treatments with proven clinical benefit for BPH outcomes 1.